An allied approach for in vitro modulation of aldose reductase, sorbitol accumulation and advanced glycation end products by flavonoid rich extract of Coriandrum sativum L. seeds
Publication date: Available online 3 August 2018Source: Toxicology ReportsAuthor(s): Anu Kajal, Randhir SinghAbstractTraditional herbal medicines are attaining more popularity and are being widely practiced. Coriandrum sativum L. is one of the oldest herbal medicinal plants valued for its nutritional and medicinal properties. Present investigation was focussed on evaluation of attenuating potential of flavonoid rich extract of C. sativum (FCS) seeds against pathogenic markers of diabetic complications i.e. advanced glycation end products (AGEs), sorbitol and aldose reductase (ALR); by using in-vitro methods. Gas chromatography-Mass spectrometry (GC-MS) and Infrared spectroscopy of FCS revealed the presence of different flavonoids.Results demonstrated that FCS has produced 79.80% inhibition of AGEs formation. Additionally, FCS was effective against sorbitol accumulation and ALR inhibition with IC50 values of 221 µg/ml and 6.08 µg/ml respectively. Molecular docking was conducted against three binding site for ALR, RAGEs and sorbitol dehydrogenase to explore their binding interactions with identified flavonoids. The constituents F2, F4 and F6 have shown good binding interactions with all the receptors. The visualisation of the docked complexes revealed the occurrence of hydrophobic forces and hydrogen bonding in receptor and docked constituents.The results were in support with experimental inhibitory activities of FCS against these biomarkers and provid...
First study of its kind to show that although low doses of statins appear protective of bone health, high doses may increase risk for osteoporosis.Medscape Medical News
Treatment with mifepristone resulted in increased levothyroxine requirements among patients with Cushing disease and central hypothyroidism.Journal of the Endocrine Society
- Collaboration combines Abbott ′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care
DiabetesMine shares a story of how the Native American population is fighting off diabetes, in the face of diet and cultural challenges.
Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes.
TYPE 2 diabetes requires careful monitoring to ward off the risk of rising blood sugar levels. Certain dietary choices have been shown to control blood sugar levels, including a certain seed.